1. Generics Bulletin
  2. >>Products

Coherus Identifies Stealing Amgen’s Crown As Pegfilgrastim Market Leader

Plans To Avoid ‘Resorting To Disproportionate Discounting’ Of Other Biosimilars

 
• By Dean Rudge

With its Udenyca pegfilgrastim biosimilar sales plunging in 2021 amid pricing and volume pressures, Coherus is looking to balance price and share trade-offs in 2022 before the intended launch of its proposed on-body injector device next year – in turn aiming to become the eventual pegfilgrastim market leader.

Arrows
Coherus is aiming to rise above innovator Amgen • Source: Shutterstock

Coherus BioSciences, Inc. has made clear its ambitions for the firm’s Udenyca (pegfilgrastim-cbqv) biosimilar, considering the progress towards commercialization for its own proposed on-body injector device that would rival Amgen’s market-leading Neulasta Onpro brand.

“Because of our on-body injector and our position within the pre-filled syringe marketplace, our vision for this brand is to become the market share leader and to overtake Amgen’s dominance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products